NetworkNewsBreaks – Moleculin Biotech, Inc. (NASDAQ: MBRX) Selects Bioscience SA as Polish CRO
Shares of Moleculin Biotech (NASDAQ: MBRX) rose 7% this morning on news that the company has selected Bioscience SA, a Polish contract research organization (CRO), to begin identifying and preparing clinical testing sites in Poland for Annamycin. The company’s drug candidate, Annamycin, is being evaluated for the treatment of relapsed or refractory acute myeloid leukemia (AML). "One of the biggest challenges for most clinical trials is recruiting the right patients on a timely basis. We believe adding Polish sites to our planned trial introduces a significant population of qualified patients, and selecting Bioscience helps ensure we reach those patients effectively…